{"id":"NCT03500094","sponsor":"Amicus Therapeutics","briefTitle":"Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)","officialTitle":"An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12 Month Treatment With Migalastat in Pediatric Subjects (Aged 12 to <18 Years) With Fabry Disease and Amenable GLA Variants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-27","primaryCompletion":"2021-02-02","completion":"2021-02-06","firstPosted":"2018-04-17","resultsPosted":"2021-11-30","lastUpdate":"2021-11-30"},"enrollment":22,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Fabry Disease"],"interventions":[{"type":"DRUG","name":"Migalastat HCl 150 mg","otherNames":["AT1001","Galafold"]}],"arms":[{"label":"migalastat HCl 150 mg","type":"EXPERIMENTAL"}],"summary":"This was an open-label study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of migalastat treatment in pediatric participants 12 to \\<18 years of age with Fabry disease and amenable gene encoding Î±-galactosidase A (GLA) variants.","primaryOutcome":{"measure":"Number Of Participants Who Experienced Treatment-related Treatment-emergent Adverse Events (TEAEs)","timeFrame":"Day 1 (after dosing) through Month 12 and follow-up (30 days after last dose)","effectByArm":[{"arm":"Migalastat HCl 150 mg","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":8,"countries":["United States","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":21},"commonTop":["Upper respiratory tract infection","Influenza","Nasopharyngitis","Back pain","Headache"]}}